×
Ardelyx Goodwill and Intangible Assets 2013-2025 | ARDX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Ardelyx goodwill and intangible assets from 2013 to 2025. Goodwill and intangible assets can be defined as the sum of all intangible asset fields
View More
Ardelyx Goodwill and Intangible Assets 2013-2025 | ARDX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Ardelyx goodwill and intangible assets from 2013 to 2025. Goodwill and intangible assets can be defined as the sum of all intangible asset fields
Related Stocks
Company Name
Market
Cap
Chugai Pharmaceutical (CHGCY)
$70.5B
Zoetis (ZTS)
$69.4B
Takeda Pharmaceutical (TAK)
$49.4B
Daiichi Sankyo, - (DSNKY)
$48.3B
BeOne Medicines - (ONC)
$34.4B
Sandoz Group AG (SDZNY)
$27.6B
Summit Therapeutics (SMMT)
$19.5B
Merck (MKKGY)
$17B
Shionogi (SGIOY)
$14.9B
United Therapeutics (UTHR)
$14.1B
Neurocrine Biosciences (NBIX)
$13.4B
IPSEN (IPSEY)
$11.4B
Orion OYJ (ORINY)
$11.3B
Eisai (ESAIY)
$9.3B
Madrigal Pharmaceuticals (MDGL)
$9.2B
Corcept Therapeutics (CORT)
$7.4B
Grifols, S.A (GRFS)
$7B
Stevanato Group S.p.A (STVN)
$6.9B
Ionis Pharmaceuticals (IONS)
$6.8B
Ono Pharmaceutical (OPHLF)
$5.7B
Hikma Pharmaceuticals Plc (HKMPF)
$5.4B
Soleno Therapeutics (SLNO)
$3.6B
Procaps Group, S.A (PROCF)
$3.2B
AMNEAL PHARMACEUTICALS, INC (AMRX)
$3B
Crinetics Pharmaceuticals (CRNX)
$2.9B
NewAmsterdam Pharma (NAMS)
$2.8B
Catalyst Pharmaceuticals (CPRX)
$2.6B
Hypermarcas (HYPMY)
$2.5B
Centessa Pharmaceuticals (CNTA)
$2.3B
Ocular Therapeutix (OCUL)
$2.1B